JP2018505158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505158A5 JP2018505158A5 JP2017536879A JP2017536879A JP2018505158A5 JP 2018505158 A5 JP2018505158 A5 JP 2018505158A5 JP 2017536879 A JP2017536879 A JP 2017536879A JP 2017536879 A JP2017536879 A JP 2017536879A JP 2018505158 A5 JP2018505158 A5 JP 2018505158A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- odd
- chain fatty
- fatty acids
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims 13
- 229930195729 fatty acid Natural products 0.000 claims 13
- 239000000194 fatty acid Substances 0.000 claims 13
- 150000004665 fatty acids Chemical class 0.000 claims 13
- 210000002966 serum Anatomy 0.000 claims 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 5
- 102000008857 Ferritin Human genes 0.000 claims 3
- 108050000784 Ferritin Proteins 0.000 claims 3
- 238000008416 Ferritin Methods 0.000 claims 3
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 102100032752 C-reactive protein Human genes 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 208000028958 Hyperferritinemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 206010065973 Iron Overload Diseases 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 108091006374 cAMP receptor proteins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000003331 prothrombotic effect Effects 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/591,660 US9561206B2 (en) | 2015-01-07 | 2015-01-07 | Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome |
| US14/591,660 | 2015-01-07 | ||
| PCT/US2015/067172 WO2016111843A1 (en) | 2015-01-07 | 2015-12-21 | Compositions and methods for diagnosis and treatment of metabolic syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020002588A Division JP2020055875A (ja) | 2015-01-07 | 2020-01-10 | 代謝症候群の診断および処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505158A JP2018505158A (ja) | 2018-02-22 |
| JP2018505158A5 true JP2018505158A5 (enExample) | 2019-01-24 |
| JP7064879B2 JP7064879B2 (ja) | 2022-05-11 |
Family
ID=55085946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536879A Active JP7064879B2 (ja) | 2015-01-07 | 2015-12-21 | 代謝症候群の診断および処置のための組成物および方法 |
| JP2020002588A Pending JP2020055875A (ja) | 2015-01-07 | 2020-01-10 | 代謝症候群の診断および処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020002588A Pending JP2020055875A (ja) | 2015-01-07 | 2020-01-10 | 代謝症候群の診断および処置のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US9561206B2 (enExample) |
| EP (2) | EP4410285A3 (enExample) |
| JP (2) | JP7064879B2 (enExample) |
| AR (1) | AR103371A1 (enExample) |
| TW (1) | TW201639557A (enExample) |
| WO (1) | WO2016111843A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10022347B2 (en) * | 2015-01-07 | 2018-07-17 | The United States Of America, As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of metabolic syndrome |
| US9561206B2 (en) * | 2015-01-07 | 2017-02-07 | The United States Of America, As Represented By The Secretary Of The Navy | Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome |
| WO2018089773A1 (en) * | 2016-11-10 | 2018-05-17 | Fractyl Laboratories, Inc. | Systems, devices, and methods for performing medical procedures in the intestine |
| US10307388B2 (en) * | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
| US10238618B2 (en) * | 2016-12-29 | 2019-03-26 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of anemia |
| WO2019083816A1 (en) * | 2017-10-23 | 2019-05-02 | Epitracker, Inc. | FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME |
| EP3793560A4 (en) * | 2018-05-16 | 2022-03-23 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF AGING-RELATED CONDITIONS |
| CA3099482A1 (en) | 2018-05-23 | 2019-11-28 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| WO2020146263A1 (en) | 2019-01-09 | 2020-07-16 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of neurodegenerative diseases |
| EP3934639A4 (en) | 2019-03-04 | 2023-01-11 | Epitracker, Inc. | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN |
| CN110129400B (zh) * | 2019-05-25 | 2023-09-01 | 华南理工大学 | 一种提高微生物油脂奇数碳链脂肪酸含量的方法 |
| WO2022040340A1 (en) * | 2020-08-20 | 2022-02-24 | Epitracker, Inc. | Compositions and methods for treatment of obesity |
| WO2022220755A1 (en) * | 2021-04-16 | 2022-10-20 | Wilmar International Limited | Triacylglycerol (tag) composition, manufacturing, and uses thereof |
| JP2024539823A (ja) | 2021-11-03 | 2024-10-31 | エピトラッカー インコーポレイテッド | 老化の質および寿命に関係する状態の治療のためのペンタデカノイルカルニチン |
| CN115894217B (zh) * | 2022-10-19 | 2025-01-17 | 福建农林大学 | 一种具有降血糖作用的十七烷酸的制备与应用 |
| WO2024206847A1 (en) * | 2023-03-31 | 2024-10-03 | Quest Diagnostics Investments Llc | Methods for quantitation of adiponectin by mass spectrometry |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2615061A1 (de) | 1976-04-05 | 1977-10-06 | Wolfgang Dr Med Wagner | Injektionsverfahren und -vorrichtungen |
| US4252159A (en) | 1979-04-02 | 1981-02-24 | Maki Eugene B | Dosage device |
| JPS60172925A (ja) * | 1984-02-17 | 1985-09-06 | Kao Corp | 胆石溶解剤 |
| JPS6115809A (ja) * | 1984-06-29 | 1986-01-23 | Lion Corp | 細胞賦活剤 |
| DE3501534A1 (de) | 1984-09-22 | 1986-05-15 | Walter Ing.(grad.) 7758 Meersburg Holzer | Verfahren und vorrichtung zum dosieren von insulin oder aehnlichen langzeitmedikamenten |
| JPS6212716A (ja) * | 1985-07-11 | 1987-01-21 | Nippon Oil & Fats Co Ltd | 制がん剤 |
| EP0317705B1 (de) | 1987-11-25 | 1992-09-30 | Siemens Aktiengesellschaft | Dosiergerät zum gesteuerten Injizieren von Flüssigkeiten aus einem Vorratsbehälter in einen Organismus |
| EP0569618B1 (de) | 1992-05-12 | 1997-01-02 | Siemens-Elema AB | Dosiergerät zur gesteuerten Abgabe einer Flüssigkeit |
| JP3558351B2 (ja) * | 1992-12-07 | 2004-08-25 | 邦郎 辻 | 免疫抑制剤 |
| AUPN137895A0 (en) * | 1995-02-27 | 1995-03-16 | Clover Corporation Pty Ltd | Composition and method |
| JP2003160486A (ja) | 2001-09-17 | 2003-06-03 | Lion Corp | 経口養育毛剤及び該養育毛剤を含有する飲食品 |
| US20030203004A1 (en) | 2002-04-24 | 2003-10-30 | Kelm Gary Robert | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| US20030203042A1 (en) * | 2002-04-24 | 2003-10-30 | Cook Lisa Ann | Compositions comprising milk protein concentrate and fatty acid and processes of their preparation |
| WO2005099483A1 (en) | 2004-04-16 | 2005-10-27 | Indevex Ab | Ingestible composition |
| US7651845B2 (en) | 2004-05-13 | 2010-01-26 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
| WO2005120484A1 (ja) | 2004-06-09 | 2005-12-22 | Kurume University | グレリンの生理学的機能のレギュレーター |
| CA2483675A1 (en) | 2004-10-01 | 2006-04-01 | Jens Peschardt | Food bar |
| US8251904B2 (en) | 2005-06-09 | 2012-08-28 | Roche Diagnostics Operations, Inc. | Device and method for insulin dosing |
| JP2008255022A (ja) | 2007-04-02 | 2008-10-23 | Kureha Corp | 抗癌性物質 |
| DE102007055636A1 (de) | 2007-11-21 | 2009-05-28 | Robert Bosch Gmbh | Medikamenten-Dosiervorrichtung zum Verabreichen eines flüssigen Medikaments |
| CN102149375B (zh) | 2008-06-11 | 2015-09-30 | 株式会社利根 | 人肾上腺素β3受体配体、含有其的食品及药品 |
| JP2010260833A (ja) | 2009-05-11 | 2010-11-18 | Daicho Kikaku:Kk | 抗自己免疫疾患剤 |
| WO2011082111A1 (en) * | 2009-12-30 | 2011-07-07 | Baylor Research Institute | Anaplerotic therapy for alzheimer's disease and the aging brain |
| US20120072236A1 (en) | 2010-08-06 | 2012-03-22 | Benjamin Atkin | Insulin pen data recording and transmission device |
| GB201020133D0 (en) * | 2010-11-26 | 2011-01-12 | Royal Holloway & Bedford New College | Therapeutic use of compounds |
| EP2673024A4 (en) | 2011-02-09 | 2017-12-20 | Becton, Dickinson and Company | Nighttime basal dosing device |
| ITMI20111284A1 (it) * | 2011-07-11 | 2013-01-12 | Giovanni Nusca | Composizione farmaceutica. |
| JP7171190B2 (ja) * | 2014-11-11 | 2022-11-15 | コーニンクレッカ フィリップス エヌ ヴェ | 線源－検出器装置 |
| US10022347B2 (en) * | 2015-01-07 | 2018-07-17 | The United States Of America, As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of metabolic syndrome |
| US9662306B2 (en) * | 2015-01-07 | 2017-05-30 | The United States Of America, As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of metabolic syndrome |
| US9561206B2 (en) * | 2015-01-07 | 2017-02-07 | The United States Of America, As Represented By The Secretary Of The Navy | Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome |
| US10307388B2 (en) | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
| US10238618B2 (en) | 2016-12-29 | 2019-03-26 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of anemia |
| JP7001554B2 (ja) * | 2018-06-27 | 2022-01-19 | ヤンマーパワーテクノロジー株式会社 | クレーン機能付き油圧ショベル |
-
2015
- 2015-01-07 US US14/591,660 patent/US9561206B2/en active Active
- 2015-12-21 EP EP24161769.5A patent/EP4410285A3/en active Pending
- 2015-12-21 WO PCT/US2015/067172 patent/WO2016111843A1/en not_active Ceased
- 2015-12-21 EP EP15823481.5A patent/EP3247346B1/en active Active
- 2015-12-21 JP JP2017536879A patent/JP7064879B2/ja active Active
- 2015-12-28 US US14/980,304 patent/US9707199B2/en active Active
- 2015-12-28 US US14/980,167 patent/US20160195558A1/en not_active Abandoned
- 2015-12-28 US US14/981,130 patent/US9713600B2/en active Active
- 2015-12-28 US US14/980,695 patent/US9687461B2/en active Active
-
2016
- 2016-01-06 AR ARP160100021A patent/AR103371A1/es unknown
- 2016-01-06 TW TW105100321A patent/TW201639557A/zh unknown
-
2019
- 2019-08-07 US US16/534,382 patent/US11116740B2/en active Active
-
2020
- 2020-01-10 JP JP2020002588A patent/JP2020055875A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505158A5 (enExample) | ||
| Wu et al. | Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-α-mediated acute liver failure induced by lipopolysaccharide/d-galactosamine | |
| RU2017115772A (ru) | Комбинация для генотерапии | |
| JP2012193216A5 (enExample) | ||
| Cui et al. | Recent advances in the pharmacological applications and liver toxicity of triptolide | |
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2009215293A5 (enExample) | ||
| HRP20192291T1 (hr) | Bardoksolon-metil, namijenjen liječenju pretilosti | |
| JP2015517488A5 (enExample) | ||
| Parlevliet et al. | GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet | |
| AR103371A1 (es) | Composiciones y métodos para diagnosis y tratamiento de síndrome metabólico, uso | |
| JP2015508765A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| Zhang et al. | Therapeutic potential and mechanisms of berberine in cardiovascular disease | |
| JP2015522603A5 (enExample) | ||
| JP2017512194A5 (enExample) | ||
| JP2017519028A5 (enExample) | ||
| JP2017014206A5 (enExample) | ||
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| JP2014533701A5 (enExample) | ||
| JP2011157375A5 (enExample) | ||
| JP2013501049A5 (enExample) | ||
| CN103239439B (zh) | 用于治疗高血脂及动脉粥样硬化的组合物及其用途 | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина |